Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SCN4A | P35499 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234481 | 0.84 | KDM4E (0.56) | HPGDSCN4ASMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL10304975 | 0.83 | TSHR (0.49) | HPGDTSHRKDM4ECYP1A2LMNA | |
| SCHEMBL11383131 | 0.83 | SCN4A (0.53) | HPGDTSHRSCN4ASMN1; SMN2KDM4E | |
| SCHEMBL22135588 | 0.83 | KDM4E (0.64) | HPGDTSHRSCN4ASMN1; SMN2KDM4E | |
| SCHEMBL2525158 | 0.83 | TSHR (0.56) | HPGDTSHRSMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL8347835 | 0.82 | KDM4E (0.59) | HPGDSCN4ASMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL25586015 | 0.82 | SCN4A (0.55) | HPGDTSHRSCN4ASMN1; SMN2KDM4E | |
| SCHEMBL15594072 | 0.82 | SCN4A (0.51) | HPGDTSHRSCN4ASMN1; SMN2KDM4E | |
| SCHEMBL9665251 | 0.82 | SCN4A (0.51) | HPGDTSHRSCN4ASMN1; SMN2KDM4E | |
| SCHEMBL16153090 | 0.82 | LMNA (0.55) | HPGDTSHRSCN4ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024031002-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023168484-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007053482-A2 | NOVEL HERBICIDE RESISTANCE GENES | DOW AGROSCIENCES LLC (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2004002483-A1 | SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-0831707-A1 | HERBICIDES WITH 4-IODO-2-[3-(4-METHOXY-6-METHYL-1,3,5-TRIAZIN-2-YL)UREIDOSULFONYL]-BENZOIC ACID ESTERS | Hoechst Schering AgrEvo GmbH (DE) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996041537-A1 | HERBICIDES WITH 4-IODO-2-[3-(4-METHOXY-6-METHYL-1,3,5-TRIAZIN-2-YL)UREIDOSULFONYL]-BENZOIC ACID ESTERS | HOECHST SCHERING AGREVO GMBH (DE) | 1996-12-27 | — | — | WO | disclosed |
| EP-0412364-A1 | Synergistic mixture of an urea and a diphenyl ether derivative for the abscission of parts of plants | BASF Aktiengesellschaft (DE) | 1991-02-13 | — | — | EP | disclosed |
| EP-0412365-A1 | Use of diphenylether derivatives for the desiccation and abscission of plant organs | BASF Aktiengesellschaft (DE) | 1991-02-13 | — | — | EP | disclosed |
| EP-0399310-A1 | 6-(Pent-3-yl)-1,2,4-triazin-5-(4H)-ones, process for their preparation and their use as herbicides and plant growth regulators | BAYER AG (DE) | 1990-11-28 | — | — | EP | disclosed |
| EP-0267412-A1 | Imidazo-pyrrolo-pyridine derivatives | BAYER AG (DE) | 1988-05-18 | — | — | EP | disclosed |
| EP-0205023-A2 | 1-Aryl-4-heterocyclyl-pyrazoles | BAYER AG (DE) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | HPGD 1731/4885TSHR 932/4885SCN4A 3633/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HPGD 173/4885TSHR 2846/4885SCN4A 1739/4885 |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | HPGD 105/4885TSHR 3065/4885SCN4A 1075/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | HPGD 2239/4885TSHR 3070/4885SCN4A 4053/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HPGD 321/4885TSHR 2455/4885SCN4A 1551/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HPGD 321/4885TSHR 2455/4885SCN4A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.